KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Other Operating Expenses (2017 - 2026)

Aurinia Pharmaceuticals filings provide 8 years of Other Operating Expenses readings, the most recent being $5.1 million for Q4 2025.

  • On a quarterly basis, Other Operating Expenses rose 12.61% to $5.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$9.5 million, a 319.23% decrease, with the full-year FY2025 number at -$9.5 million, down 319.23% from a year prior.
  • Other Operating Expenses hit $5.1 million in Q4 2025 for Aurinia Pharmaceuticals, up from -$929000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $5.1 million in Q4 2025 to a low of -$9.2 million in Q2 2025.
  • Median Other Operating Expenses over the past 5 years was $115000.0 (2021), compared with a mean of -$630650.0.
  • Biggest five-year swings in Other Operating Expenses: soared 1543.28% in 2021 and later plummeted 3288.28% in 2025.
  • Aurinia Pharmaceuticals' Other Operating Expenses stood at $285000.0 in 2021, then surged by 661.4% to $2.2 million in 2022, then crashed by 518.16% to -$9.1 million in 2023, then skyrocketed by 149.66% to $4.5 million in 2024, then rose by 12.61% to $5.1 million in 2025.
  • The last three reported values for Other Operating Expenses were $5.1 million (Q4 2025), -$929000.0 (Q3 2025), and -$9.2 million (Q2 2025) per Business Quant data.